[go: up one dir, main page]

EE04752B1 - Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine - Google Patents

Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine

Info

Publication number
EE04752B1
EE04752B1 EEP200000068A EEP200000068A EE04752B1 EE 04752 B1 EE04752 B1 EE 04752B1 EE P200000068 A EEP200000068 A EE P200000068A EE P200000068 A EEP200000068 A EE P200000068A EE 04752 B1 EE04752 B1 EE 04752B1
Authority
EE
Estonia
Prior art keywords
antibody
hybridoma producing
monoclonal antibody
monoclonal
integrin
Prior art date
Application number
EEP200000068A
Other languages
English (en)
Estonian (et)
Inventor
Huang Xiaozhu
Sheppard Dean
Pytela Robert
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of EE200000068A publication Critical patent/EE200000068A/xx
Publication of EE04752B1 publication Critical patent/EE04752B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000068A 1997-08-08 1998-08-07 Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine EE04752B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (2)

Publication Number Publication Date
EE200000068A EE200000068A (et) 2000-10-16
EE04752B1 true EE04752B1 (et) 2006-12-15

Family

ID=21995323

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000068A EE04752B1 (et) 1997-08-08 1998-08-07 Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine

Country Status (23)

Country Link
US (5) US20020004482A1 (hu)
EP (3) EP0996460B1 (hu)
JP (2) JP2001513333A (hu)
KR (1) KR100586202B1 (hu)
CN (1) CN1267224A (hu)
AT (3) ATE511850T1 (hu)
AU (1) AU739283B2 (hu)
BR (1) BR9814040A (hu)
CA (1) CA2297736A1 (hu)
CY (2) CY1110462T1 (hu)
CZ (1) CZ299768B6 (hu)
DE (2) DE69840113D1 (hu)
DK (2) DK1504764T3 (hu)
EE (1) EE04752B1 (hu)
ES (3) ES2364703T3 (hu)
HU (1) HU228900B1 (hu)
IL (2) IL134288A0 (hu)
NZ (2) NZ515955A (hu)
PL (2) PL201716B1 (hu)
PT (3) PT1504764E (hu)
RU (1) RU2221589C2 (hu)
TR (2) TR200202323T2 (hu)
WO (1) WO1999007405A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
DE69840113D1 (de) * 1997-08-08 2008-11-20 Univ California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern
ATE298249T1 (de) * 1999-04-22 2005-07-15 Biogen Idec Inc Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
WO2002088307A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2008112004A2 (en) * 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
DK2185198T3 (en) * 2007-08-02 2015-04-20 Gilead Biologics Inc LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
EP2470218A4 (en) * 2009-08-21 2013-04-03 Gilead Biologics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROGEN DISORDERS
SG183174A1 (en) * 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
BR112014019861A2 (pt) 2012-02-17 2017-07-04 Seattle Genetics Inc anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
BR112020003498A2 (pt) 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
JP7551750B2 (ja) 2019-12-05 2024-09-17 シージェン インコーポレイテッド 抗αｖβ６抗体及び抗体薬物コンジュゲート
US20230181546A1 (en) * 2020-05-07 2023-06-15 Pliant Therapeutics, Inc. Treatment of respiratory diseases with amino acid compounds
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
AU628910B2 (en) 1988-12-20 1992-09-24 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
PT719859E (pt) * 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
DE69840113D1 (de) * 1997-08-08 2008-11-20 Univ California Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern

Also Published As

Publication number Publication date
DK1504764T3 (da) 2008-11-17
TR200000374T2 (tr) 2000-09-21
PL199014B1 (pl) 2008-08-29
ES2364703T3 (es) 2011-09-12
US20010056076A1 (en) 2001-12-27
US20070148173A1 (en) 2007-06-28
CN1267224A (zh) 2000-09-20
NZ502546A (en) 2002-02-01
ES2311131T3 (es) 2009-02-01
HU228900B1 (en) 2013-06-28
CZ299768B6 (cs) 2008-11-19
JP2009001587A (ja) 2009-01-08
KR20010022740A (ko) 2001-03-26
DE69828614T2 (de) 2006-02-09
HUP0003547A2 (hu) 2001-02-28
HUP0003547A3 (en) 2002-05-28
ATE286742T1 (de) 2005-01-15
CA2297736A1 (en) 1999-02-18
US7544358B2 (en) 2009-06-09
DK1930022T3 (da) 2011-07-25
PL201716B1 (pl) 2009-05-29
EP1504764B1 (en) 2008-10-08
EP1504764A1 (en) 2005-02-09
US7150871B2 (en) 2006-12-19
US6692741B2 (en) 2004-02-17
EP1930022A1 (en) 2008-06-11
RU2221589C2 (ru) 2004-01-20
AU8774398A (en) 1999-03-01
IL134288A0 (en) 2001-04-30
EP0996460A1 (en) 2000-05-03
DE69828614D1 (de) 2005-02-17
DE69840113D1 (de) 2008-11-20
IL134288A (en) 2008-07-08
ATE511850T1 (de) 2011-06-15
PT1930022E (pt) 2011-08-01
EE200000068A (et) 2000-10-16
TR200202323T2 (tr) 2002-12-23
PL341029A1 (en) 2001-03-26
ATE410179T1 (de) 2008-10-15
CY1111792T1 (el) 2015-10-07
KR100586202B1 (ko) 2006-06-07
ES2235350T3 (es) 2005-07-01
CY1110462T1 (el) 2015-04-29
US20040208878A1 (en) 2004-10-21
JP2001513333A (ja) 2001-09-04
EP0996460A4 (en) 2001-03-07
EP1930022B1 (en) 2011-06-08
CZ2000413A3 (cs) 2000-11-15
US20020004482A1 (en) 2002-01-10
EP0996460B1 (en) 2005-01-12
NZ515955A (en) 2003-04-29
PT996460E (pt) 2005-04-29
US6316601B1 (en) 2001-11-13
WO1999007405A1 (en) 1999-02-18
BR9814040A (pt) 2000-10-03
PT1504764E (pt) 2009-01-14
AU739283B2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
SI1007089T1 (sl) Antikoagulantska humanizirana protitelesa proti faktorju IX za uporabo pri zdravljenju tromboze
NZ288883A (en) Conjugates comprising coagulation factors
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
CY2013010I2 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
ATE373712T1 (de) Natürlicher menschlicher antikörper
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
WO2001005425A3 (en) Combined preparations comprising daunorubicin derivatives and her2 antibodies
WO2003026692A3 (en) Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
TW200517124A (en) Fully human antibodies against human 4-1BB
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
ZA986064B (en) Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use.
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
GEP20043233B (en) Composition Containing Blocking Monoclonal Antibody VLA-1

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231